[0366] Figure 2 shows the relative hDMPK transcript levels of the test groups. The hDMPK transcript levels are shown normalized to Group 2. Figure 2 shows introducing AC002324 inhibits hDMPK transcript levels.

[0367] Figures 3 through 6 show relative missplicing of mCacna1, mLdb3, mMbnl1, and mAtp2a1 of the test groups. The relative missplicing levels are normalized to Group 2. Figures 3 through 6 show introducing DMPK RNAi agent AC002324 prevents splicing of these measured genes.

[0368] For Figures 2 through 6, the statistical significance is represented by: * is $p < 0.05$, ** is $p < 0.01$, *** is $p < 0.001$, and **** is $p < 0.0001$.

Example 19. In Vivo Testing of DMPK RNAi Agents in Cynomolgus Monkeys.

[0369] Cynomolgus study animals were weighed and dosed on Day 1 via intravenous route of injection. Muscle biopsies were collected on Days -14 (pre-treatment), 29, and 57. At each timepoint, the cynomolgus study animals were fasted overnight (at least 12 but no more than 18 hours). The animals were dosed in accordance with Table 37.

[0370] Table 37. DMPK RNAi Agent and Dosing for Example 19

Group ID	Dose	Dose Volume	Number of Animals (n =)
Group 1 10 mg/kg AC002324	Single intravenous (i.v.) injection on day 1	1.0 ml/kg	3
Group 2 10 mg/kg AC002690	Single intravenous (i.v.) injection on day 1	1.0 ml/kg	3
Group 3 10 mg/kg AC002691	Single intravenous (i.v.) injection on day 1	1.0 ml/kg	3

[0371] Individual doses were calculated based on body weights recorded on each day of dosing. Test articles were administered as a single intravenous (i.v.) injection utilizing the cephalic vein. For Groups 1-3, IV injection volume was slowly administered over 1 minute.